Drug Trial Radar · NCT00424476
A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)
Last checked: Nov 20, 2026Latest source record: Dec 12, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
865
Actual
Start
May 2007
Primary completion
May 2009
Study completion Mar 2010
Sponsor
- Lead sponsor
- Human Genome Sciences Inc.Industry
- Sponsor type
- Industry
- Collaborators
- GlaxoSmithKline
- First posted
- Jan 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.
Conditions
- Systemic Lupus Erythematosus
Interventions
PlaceboDrug
Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Belimumab 1 mg/kgDrug
Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Belimumab 10 mg/kgDrug
Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
Primary outcomes
What the sponsor says the trial is designed to measure.
- SLE Responder Index (SRI) Response Rate at Week 52Time frame: Baseline, 52 weeks
Locations
92 sites in 13 countries. Site status is shown where the registry gives one.
OMI, Organización Médica de Investigación
Buenos Aires, Argentina
CIER, Centro de Investigaciones en Enfermedades Reumáticas
Buenos Aires, Argentina
Hospital Britanico de Buenos Aires
Buenos Aires, Argentina
Hospital General de Agudos Carlos G. Durand
Buenos Aires, Argentina
Centro Privado de Medicina Familiar
Buenos Aires, Argentina
Hospital Sirio Libanes
Buenos Aires, Argentina
Atencion Integral en Reumatologia
Buenos Aires, Argentina
Instituto de Investigaciones Medicas
Buenos Aires, Argentina
Hospital Interzonal General San Martín
La Plata, Argentina
CAICI, Instituto Centralizado de Asistencia e Investigación Clínica Integral
Rosario, Argentina
Centro Medico Privado de Reumatologia
San Miguel de Tucumán, Argentina
Repatriation Hospital
Daw Park, Australia
Emeritus Research, Cabrini Hospital
Melbourne, Australia
Monash Medical Centre
Melbourne, Australia
Royal Perth Hospital
Shenton Park, Australia
Hospital de Clínicas - UNICAMP
Campinas, Brazil
Hospital das Clínicas - Universidade do Paraná
Curitiba, Brazil
Hospital de Clínicas - Universidade Federal de Pernambuco
Fortaleza, Brazil
Hospital Geral de Goiânia
Goiânia, Brazil
Hospital Universitário - Universidade Federal de Juiz de Fora
Juiz de Fora, Brazil
Hospital São Lucas da PUC-RS
Porto Alegre, Brazil
Hospital Universitário Pedro Ernesto - UERJ
Rio de Janeiro, Brazil
Hospital Unversitario Clementino Fraga Filho UFRJ
Rio de Janeiro, Brazil
Hospital Santa Izabel
Salvador, Brazil
Hospital Abreu Sodré
São Paulo, Brazil
Hospital do Servidor Público Estadual de São Paulo - Francisco Morato de Oliveira
São Paulo, Brazil
Hospital Heliópolis
São Paulo, Brazil
Hospital Dr. Sotero del Rio
Santiago, Chile
Pontificia Universidad Católica de Chile
Santiago, Chile
Clínica Dávila
Santiago, Chile
Hospital Dr. Gustavo Fricke
Viña del Mar, Chile
Centro de Reumatologia y Ortopedia
Barranquilla, Colombia
Centrode de Investigaciones en Reumatologia Especialidades Medicas (CIREEH)
Bogotá, Colombia
Fundación Instituto de Reumatología Fernando Chalem
Bogotá, Colombia
Riesgo de Fracturas
Bogotá, Colombia
SERVIMED
Bucaramanga, Colombia
Corporación para Investigaciones Biológicas (CIB)
Medellín, Colombia
Office of Dr. Jose Molina
Medellín, Colombia
Office of Dr. Guzman
Bogota, Cundinamarca, Colombia
Fundación Oftalmologica de Santander Clinica Carlos Ardila Lulle
Bucaramanga, Santander Department, Colombia
Showing 40 of 92 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.